Retreatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen (BCR) significantly improves PFS in patients with EOC

✍ Scribed by G. McCann; B. Smith; F. Backes; K. Rath; R. Salani; E. Eisenhauer; J. Fowler; L. Copeland; D. Cohn

• Book ID: 113963724
• Publisher: Elsevier Science
• Year: 2012
• Tongue: English
• Weight: 58 KB
• Volume: 125
• Category: Article
• ISSN: 0090-8258
• DOI: 10.1016/j.ygyno.2011.12.169